• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 10:05:46 AM ET
    $ZIOP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZIOP alert in real time by email
    SC 13G/A 1 ziopa2_21621.htm MILLER VALUE PARTNERS, LLC ziopa2_21621.htm
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 2)*
    Ziopharm Oncology, Inc.
    (Name of Issuer)
    Common Stock
    (Title of Class of Securities)
    98973P101
    (CUSIP Number)
    December 31, 2020
    (Date of Event which Requires Filing of this Statement)
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [X] Rule 13d-1(b)
    [   ] Rule 13d-1(c)
    [   ] Rule 13d-1(d)
    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see Instructions).
    CUSIP No.: 98973P101
           
    1
    NAME OF REPORTING PERSON
    Miller Value Partners, LLC
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    52-2204753
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    0
    6
    SHARED VOTING POWER
    16,254,127
    7
    SOLE DISPOSITIVE POWER
    0
    8
    SHARED DISPOSITIVE POWER
    16,254,127
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    16,254,127
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    7.45%
    12
    TYPE OF REPORTING PERSON
    IA
    CUSIP No.: 98973P101
           
    1
    NAME OF REPORTING PERSON
    William H. Miller III Living Trust (the "Trust")
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    United States Citizen
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    0
    6
    SHARED VOTING POWER
    16,254,127
    7
    SOLE DISPOSITIVE POWER
    0
    8
    SHARED DISPOSITIVE POWER
    16,254,127
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    16,254,127 (The Trust is deemed to be the beneficial owner of 16,254,127 shares of common stock owned by clients of Miller Value Partners, LLC.)
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    7.45%
    12
    TYPE OF REPORTING PERSON
    OO - The Trust is a living trust organized under the laws of the State of Florida
    CUSIP No.: 98973P101
           
    1
    NAME OF REPORTING PERSON
    Miller Opportunity Trust, a series of Trust for Advised Portfolios
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    52-2203385
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    0
    6
    SHARED VOTING POWER
    13,187,879
    7
    SOLE DISPOSITIVE POWER
    0
    8
    SHARED DISPOSITIVE POWER
    13,187,879
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    13,187,879 (this amount is also included in the aggregate amount reported by Miller Value Partners, LLC & William H. Miller III Living Trust)
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    6.05%
    12
    TYPE OF REPORTING PERSON
    IV
    CUSIP No.: 98973P101
    ITEM 1(a). NAME OF ISSUER:
    Ziopharm Oncology, Inc.
    ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
    One First Avenue, Parris Building 34, Navy Yard Plaza
    Boston, Massachusetts 02129
    ITEM 2(a). NAME OF PERSON FILING:
    Miller Value Partners, LLC
    William H. Miller III Living Trust (the "Trust")
    Miller Opportunity Trust, a series of Trust for Advised Portfolios
    ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
    One South Street
    Suite 2550
    Baltimore, MD 21202
    ITEM 2(c). CITIZENSHIP:
    Delaware
    United States of America
    Delaware
    ITEM 2(d). TITLE OF CLASS OF SECURITIES:
    Common Stock
    ITEM 2(e). CUSIP NUMBER:
    98973P101
    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTION 240.13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS A:
    (a)
    [ ]
    Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78c);
    (b)
    [ ]
    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)
    [ ]
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)
    [X]
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
    (e)
    [X]
    An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
    (f)
    [ ]
    An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
    (g)
    [X]
    A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
    (h)
    [ ]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)
    [ ]
    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)
    [ ]
    A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J);
    (k)
    [ ]
    Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d1(b)(1)(ii)(J), please specify the type of institution:
    ITEM 4. OWNERSHIP
    (a) Amount beneficially owned:
    1) Miller Value Partners, LLC is deemed to be the beneficial owner of 16,254,127 shares of common stock, which consists of 12,466,248 common shares and 3,787,879 shares issuable upon the exercise of certain warrants and deemed outstanding for purposes of calculating beneficial ownership.

    2) The Trust is deemed to be the beneficial owner of 16,254,127 shares of common stock owned by clients of Miller Value Partners, LLC, which consists of 12,466,248 common shares and 3,787,879 shares issuable upon the exercise of certain warrants and deemed outstanding for purposes of calculating beneficial ownership.

    3) Miller Opportunity Trust, a series of Trust for Advised Portfolios is deemed to be the beneficial owner of 13,187,879 shares of common stock, which consists of 9,400,000 common shares and 3,787,879 shares issuable upon the exercise of certain warrants and deemed outstanding for purposes of calculating beneficial ownership.
    (b) Percent of class:
    1) Miller Value Partners, LLC - 7.45%
    2) Trust - 7.45%
    3) Miller Opportunity Trust, a series of Trust for Advised Portfolios - 6.05%
    (c) Number of shares as to which the person has:
    (i) sole power to vote or to direct the vote:
    1) Miller Value Partners, LLC - 0
    2) Trust - 0
    3) Miller Opportunity Trust, a series of Trust for Advised Portfolios - 0
    (ii) shared power to vote or to direct the vote:
    1) Miller Value Partners, LLC - 16,254,127
    2) Trust - 16,254,127
    3) Miller Opportunity Trust, a series of Trust for Advised Portfolios - 13,187,879
    (iii) sole power to dispose or direct the disposition of:
    1) Miller Value Partners, LLC - 0
    2) Trust - 0
    3) Miller Opportunity Trust, a series of Trust for Advised Portfolios - 0
    (iv) shared power to dispose or to direct the disposition of:
    1) Miller Value Partners, LLC - 16,254,127
    2) Trust - 16,254,127
    3) Miller Opportunity Trust, a series of Trust for Advised Portfolios - 13,187,879
    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].
    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
    Various accounts managed by Miller Value Partners, LLC have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities. The interest of one account, Miller Opportunity Trust, a series of Trust for Advised Portfolios, an investment company registered under the Investment Company Act of 1940 and managed by Miller Value Partners, LLC was deemed to be the beneficial owner of 13,187,879 shares or 6.05% of the total shares outstanding as of December 31, 2020.
    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
    See Exhibit A
    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
    N/A
    ITEM 9. NOTICE OF DISSOLUTION OF GROUP:
    N/A
    ITEM 10. CERTIFICATION:
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
    CUSIP No.: 98973P101
    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    February 16 2021
    Miller Value Partners, LLC
    By:
    /s/ Neil O'Callaghan
    Name:
    Neil O'Callaghan
    Title:
    President & Chief Compliance Officer
    February 16 2021
    William H. Miller III Living Trust
    By:
    /s/ Neil O'Callaghan
    Name:
    Duly authorized under the Power of Attorney effective as of January 30, 2019, by and on behalf of William H. Miller III Living Trust. This Power of Attorney is incorporated herein by reference to Exhibit B to the Schedule 13G filed by Miller Value Partners, LLC on February 11, 2019, accession number 0001085146-19-000481.
    Title:
    February 16 2021
    Miller Opportunity Trust, a series of Trust for Advised Portfolios
    By:
    /s/Russell B. Simon
    Name:
    Russell B. Simon
    Title:
    CFO/Treasurer
    Attention — Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).
    CUSIP No.: 98973P101
    Exhibit A

    Joint Filing Agreement

    Miller Value Partners, LLC (an investment adviser registered under the Investment Advisers Act of 1940), its control person, William H. Miller III Living Trust, and Miller Opportunity Trust, a series of Trust for Advised Portfolios (a registered investment company), hereby agree to file jointly the statement on Schedule 13G to which this Agreement is attached, and any amendments thereto which may be deemed necessary, pursuant to Regulation 13D-G under the Securities Exchange Act of 1934.

    It is understood and agreed that each of the parties hereto is responsible for the timely filing of such statement and any amendments thereto, and for the completeness and accuracy of the information concerning such party contained therein, but such party is not responsible for the completeness or accuracy of information concerning the other party unless such party knows or has reason to believe that such information is inaccurate.


    Miller Value Partners, LLC
    Date: February 16, 2021
    Signature: /s/ Neil O'Callaghan
    Name & Title: Neil O'Callaghan, President & Chief Compliance Officer


    William H. Miller III Living Trust
    Date: February 16, 2021
    Signature: /s/ Neil O'Callaghan
    Duly authorized under the Power of Attorney effective as of January 30, 2019, by and on behalf of William H. Miller III Living Trust.**


    Miller Opportunity Trust, a series of Trust for Advised Portfolios
    Date: February 16, 2021
    Signature: /s/ Russell B. Simon
    Name & Title: Russell B. Simon, CFO/Treasurer

    **This Power of Attorney is incorporated herein by reference to Exhibit B to the Schedule 13G filed by Miller Value Partners, LLC on February 11, 2019, accession number 0001085146-19-000481.

    Get the next $ZIOP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ZIOP

    DatePrice TargetRatingAnalyst
    11/9/2021$3.00 → $2.00Market Perform
    Raymond James
    8/10/2021Outperform → Mkt Perform
    Raymond James
    8/10/2021$3.00Outperform → Market Perform
    Raymond James
    More analyst ratings

    $ZIOP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CARsgen Appoints Dr. Raffaele Baffa as Chief Medical Officer

      SHANGHAI and BOSTON, April 7, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T cell therapies for the treatment of hematologic malignancies and solid tumors, announces that Dr. Raffaele Baffa ("Dr. Baffa") has been appointed as the Chief Medical Officer ("CMO") of the Company, responsible for overseeing the global clinical development strategies and operations for the Company's innovative pipeline product candidates. Dr. Baffa will report to Dr. Zonghai Li, Founder, Chairman of the Board, CEO, CSO of CARsgen Therapeutics Holdings Limited. Dr. Baffa has rich experiences in pharmaceutical industry and research institutes,

      4/7/22 11:42:00 AM ET
      $TCRT
      $ZIOP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ziopharm Oncology Highlights Operational Progress & Rebrands to Alaunos Therapeutics

      Phase 1/2 TCR-T Library trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications is open for enrollment; continue to expect to dose the first patient in 1H 2022 Phase 1/2 IND amended to include four additional TCRs, bringing the total number of evaluable TCRs to 10, further expanding number of eligible patientsIn-house cGMP manufacturing facility is operational to support internal clinical development programsCompany changes name to Alaunos Therapeutics reflecting renewed focus HOUSTON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP), a clinical-stage oncology-focused cell therapy company, today highlighted rec

      1/26/22 7:00:00 AM ET
      $ZIOP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ziopharm Oncology Presents Preclinical Data Supporting TCR-T Library Approach at the Society for Immunotherapy of Cancer 2021 Annual Meeting

      HOUSTON, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP), today announced the presentation of preclinical data highlighting the potential of neoantigen-specific TCR-T cells for the treatment of solid tumors at the Society for Immunotherapy of Cancer 2021 Annual Meeting. "We are pleased to share preclinical data demonstrating the versatility of our Sleeping Beauty technology to develop neoantigen-specific TCR-T cells with the potential to address a wide range of solid tumor indications," commented Raffaele Baffa, M.D., Ph.D., Chief Medical Officer & EVP, Research & Development. "Our TCR-T library approach allows us to develop safe, effe

      11/9/21 8:05:00 AM ET
      $ZIOP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZIOP
    Leadership Updates

    Live Leadership Updates

    See more
    • CARsgen Appoints Dr. Raffaele Baffa as Chief Medical Officer

      SHANGHAI and BOSTON, April 7, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T cell therapies for the treatment of hematologic malignancies and solid tumors, announces that Dr. Raffaele Baffa ("Dr. Baffa") has been appointed as the Chief Medical Officer ("CMO") of the Company, responsible for overseeing the global clinical development strategies and operations for the Company's innovative pipeline product candidates. Dr. Baffa will report to Dr. Zonghai Li, Founder, Chairman of the Board, CEO, CSO of CARsgen Therapeutics Holdings Limited. Dr. Baffa has rich experiences in pharmaceutical industry and research institutes,

      4/7/22 11:42:00 AM ET
      $TCRT
      $ZIOP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ziopharm Oncology Announces Election of James Huang as Chairman of the Board of Directors

      – Mr. Huang is a veteran industry entrepreneur with 20+ years founding and funding biotech innovation – – Heidi Hagen elected Lead Independent Director – BOSTON, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP) today announced the election of James Huang as Chairman of the Board of Directors (the “Board”), effective immediately. Mr. Huang has served on the Board since July 2020 and is currently a Managing Partner at Kleiner Perkins Caufield & Byers (KPCB) China. He has founded and financed several innovative life sciences companies, including GenScript, Legend Biotech and Zai Lab. He is also Founding Partner of Panacea Venture, which

      1/14/21 8:00:00 AM ET
      $ZIOP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ziopharm Details Actions in Response to Shareholder Feedback

      Has Held Several Discussions with WaterMill to Reach an Amicable Resolution to Consent Solicitation Board Accepts Resignation of Director Elan Ezickson Reiterates Concerns About Professional Past of WaterMill Nominee Holger Weis BOSTON, Dec. 04, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP) (“Ziopharm” or the “Company”), today announced that it has sent a letter to shareholders urging them to support the Company’s continued progress and long-term prospects. The letter was sent in connection with the Company’s definitive consent revocation statement in response to the consent solicitation initiated by WaterMill Asset

      12/4/20 8:30:00 AM ET
      $ZIOP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZIOP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Raymond James reiterated coverage on ZIOPHARM Oncology with a new price target

      Raymond James reiterated coverage of ZIOPHARM Oncology with a rating of Market Perform and set a new price target of $2.00 from $3.00 previously

      11/9/21 7:43:39 AM ET
      $ZIOP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ZIOPHARM downgraded by Raymond James

      Raymond James downgraded ZIOPHARM from Outperform to Mkt Perform

      8/10/21 6:27:29 AM ET
      $ZIOP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ZIOPHARM Oncology downgraded by Raymond James with a new price target

      Raymond James downgraded ZIOPHARM Oncology from Outperform to Market Perform and set a new price target of $3.00

      8/10/21 5:08:16 AM ET
      $ZIOP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZIOP
    SEC Filings

    See more
    • ZIOPHARM Oncology Inc filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Alaunos Therapeutics, Inc. (0001107421) (Filer)

      1/26/22 7:28:02 AM ET
      $ZIOP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ZIOPHARM Oncology Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities

      8-K - ZIOPHARM ONCOLOGY INC (0001107421) (Filer)

      1/4/22 4:05:59 PM ET
      $ZIOP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by ZIOPHARM Oncology Inc

      10-Q - ZIOPHARM ONCOLOGY INC (0001107421) (Filer)

      11/8/21 4:10:47 PM ET
      $ZIOP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZIOP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: De Groot Eleanor sold $25,568 worth of shares (20,132 units at $1.27) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 237,106 units (tax withholding)

      4 - ZIOPHARM ONCOLOGY INC (0001107421) (Issuer)

      12/27/21 12:20:38 PM ET
      $ZIOP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Lackey Melinda

      4 - ZIOPHARM ONCOLOGY INC (0001107421) (Issuer)

      12/13/21 6:06:48 AM ET
      $ZIOP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Lackey Melinda

      3 - ZIOPHARM ONCOLOGY INC (0001107421) (Issuer)

      12/9/21 2:33:03 PM ET
      $ZIOP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZIOP
    Financials

    Live finance-specific insights

    See more
    • Ziopharm Oncology Reports Third Quarter 2021 Financial Results and Provides Business Update

      HOUSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP), today announced financial results for the third quarter ended September 30, 2021 and provided a business update. "I am impressed by the quality and dedication of our team at Ziopharm who all are diligently working to transform our cutting-edge scientific research into meaningful clinical progress. Last quarter we made the decision to restructure the organization and focus our efforts on advancing our differentiated TCR-T library towards the clinic," said Kevin S. Boyle, Sr., Chief Executive Officer at Ziopharm Oncology. "We are making excellent progress to operationa

      11/8/21 4:10:00 PM ET
      $ZIOP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ziopharm Oncology to Report Third Quarter Financial Results on November 8, 2021

      HOUSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP), today announced that it will report financial results for the third quarter ended September 30, 2021 on Monday, November 8, 2021, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 4:30 p.m. ET to provide a corporate update and review the financial results. The conference call can be accessed by dialing 877-451-6152 (United States) or 201-389-0879 (International) with the conference code 13724384. A live webcast may be accessed using the link here, or by visiting the "Investors" section of the Ziopharm website at w

      11/1/21 4:30:00 PM ET
      $ZIOP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ziopharm Oncology Appoints Kevin S. Boyle, Sr., as Chief Executive Officer and Announces other Executive Promotions

      Mr. Boyle brings over 20 years of executive business leadership in CEO, CFO and operational leadership roles Strong track record of successfully guiding companies and creating shareholder value through disciplined capital management and achievement of milestones Raffaele Baffa MD, Ph.D. appointed Head of Research and Development in addition to Chief Medical Officer Adam Levy, Ph.D., MBA appointed Executive Vice President, Corporate Development and Investor Relations Conference call scheduled for today at 4:30 pm EDT BOSTON and HOUSTON, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP), today announced the appointment of Kevin S. Boyl

      8/30/21 8:30:00 AM ET
      $ZIOP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZIOP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by ZIOPHARM Oncology Inc (Amendment)

      SC 13G/A - ZIOPHARM ONCOLOGY INC (0001107421) (Subject)

      10/12/21 1:40:54 PM ET
      $ZIOP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - ZIOPHARM ONCOLOGY INC (0001107421) (Subject)

      2/16/21 1:10:00 PM ET
      $ZIOP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - ZIOPHARM ONCOLOGY INC (0001107421) (Subject)

      2/16/21 10:05:46 AM ET
      $ZIOP
      Biotechnology: Pharmaceutical Preparations
      Health Care